Adherence and persistence to direct oral anticoagulants in atrial fibrillation:population-based study

Amitava Banerjee, PHILLIP KARANJA GICHURU

Research output: Contribution to journalArticle

2 Downloads (Pure)

Abstract

Background: Despite simpler regimes than vitamin K antagonists(VKA) for stroke prevention in atrial fibrillation(AF), adherence(taking drugs as prescribed) and persistence(continuation of drugs) to direct oral anticoagulants(DOACs) are suboptimal, yet understudied in electronic health records(EHR).

Objective: We investigated: (i)time trends at individual and system levels; (ii)risk factors for and associations between adherence and persistence.

Methods: In UK primary care EHR(The Health Information Network; 2011-2016), we investigated adherence and persistence at 1-year for OACs in adults with incident AF. Baseline characteristics were analysed by OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed using Cox and logistic regression. Patterns of adherence and persistence were analysed.

Results: Among 36652 individuals with incident AF, cardiovascular comorbidities(median CHA2DS2VASc 3) and polypharmacy(median number of drugs 6) were common. Adherence was 55.2%(95 CI 54.6-55.7), 51.2%(50.6-51.8), 66.5%(63.7-69.2), 63.1%(61.8-64.4) and 64.7(63.2-66.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. One-year persistence was 65.9%(65.4-66.5), 63.4%(62.8-64.0), 61.4%(58.3-64.2), 72.3%(70.9-73.7) and 78.7%(77.1-80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing comorbidity was associated with reduced risk of non-adherence and non-persistence, across all OACs. Overall rates of “primary non-adherence”(stopping after first prescription), “non-adherent non-persistence” and “persistent adherence” were 3.5%, 26.5% and 40.2%, differing across OACs.

Conclusions: Adherence and persistence to OACs are low at one year with heterogeneity across drugs and over time, at individual and system levels. Better understanding of contributory factors will inform interventions to improve adherence and persistence across OACs in individuals and populations.

Key words: atrial fibrillation, anticoagulant, adherence, persistence, stroke
Original languageEnglish
JournalHeart
Early online date10 Oct 2019
Publication statusE-pub ahead of print - 10 Oct 2019

Fingerprint

Anticoagulants
Atrial Fibrillation
Vitamin K
Electronic Health Records
Pharmaceutical Preparations
Population
Comorbidity
Stroke
Polypharmacy
Information Services
Prescriptions
Primary Health Care
Logistic Models
Health
Rivaroxaban
apixaban
Dabigatran

Cite this

@article{550adb13d2724ea49a8589e6cd0cfcf0,
title = "Adherence and persistence to direct oral anticoagulants in atrial fibrillation:population-based study",
abstract = "Background: Despite simpler regimes than vitamin K antagonists(VKA) for stroke prevention in atrial fibrillation(AF), adherence(taking drugs as prescribed) and persistence(continuation of drugs) to direct oral anticoagulants(DOACs) are suboptimal, yet understudied in electronic health records(EHR). Objective: We investigated: (i)time trends at individual and system levels; (ii)risk factors for and associations between adherence and persistence.Methods: In UK primary care EHR(The Health Information Network; 2011-2016), we investigated adherence and persistence at 1-year for OACs in adults with incident AF. Baseline characteristics were analysed by OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed using Cox and logistic regression. Patterns of adherence and persistence were analysed. Results: Among 36652 individuals with incident AF, cardiovascular comorbidities(median CHA2DS2VASc 3) and polypharmacy(median number of drugs 6) were common. Adherence was 55.2{\%}(95 CI 54.6-55.7), 51.2{\%}(50.6-51.8), 66.5{\%}(63.7-69.2), 63.1{\%}(61.8-64.4) and 64.7(63.2-66.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. One-year persistence was 65.9{\%}(65.4-66.5), 63.4{\%}(62.8-64.0), 61.4{\%}(58.3-64.2), 72.3{\%}(70.9-73.7) and 78.7{\%}(77.1-80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing comorbidity was associated with reduced risk of non-adherence and non-persistence, across all OACs. Overall rates of “primary non-adherence”(stopping after first prescription), “non-adherent non-persistence” and “persistent adherence” were 3.5{\%}, 26.5{\%} and 40.2{\%}, differing across OACs.Conclusions: Adherence and persistence to OACs are low at one year with heterogeneity across drugs and over time, at individual and system levels. Better understanding of contributory factors will inform interventions to improve adherence and persistence across OACs in individuals and populations.Key words: atrial fibrillation, anticoagulant, adherence, persistence, stroke",
author = "Amitava Banerjee and GICHURU, {PHILLIP KARANJA}",
year = "2019",
month = "10",
day = "10",
language = "English",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",

}

Adherence and persistence to direct oral anticoagulants in atrial fibrillation:population-based study. / Banerjee, Amitava ; GICHURU, PHILLIP KARANJA.

In: Heart, 10.10.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adherence and persistence to direct oral anticoagulants in atrial fibrillation:population-based study

AU - Banerjee, Amitava

AU - GICHURU, PHILLIP KARANJA

PY - 2019/10/10

Y1 - 2019/10/10

N2 - Background: Despite simpler regimes than vitamin K antagonists(VKA) for stroke prevention in atrial fibrillation(AF), adherence(taking drugs as prescribed) and persistence(continuation of drugs) to direct oral anticoagulants(DOACs) are suboptimal, yet understudied in electronic health records(EHR). Objective: We investigated: (i)time trends at individual and system levels; (ii)risk factors for and associations between adherence and persistence.Methods: In UK primary care EHR(The Health Information Network; 2011-2016), we investigated adherence and persistence at 1-year for OACs in adults with incident AF. Baseline characteristics were analysed by OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed using Cox and logistic regression. Patterns of adherence and persistence were analysed. Results: Among 36652 individuals with incident AF, cardiovascular comorbidities(median CHA2DS2VASc 3) and polypharmacy(median number of drugs 6) were common. Adherence was 55.2%(95 CI 54.6-55.7), 51.2%(50.6-51.8), 66.5%(63.7-69.2), 63.1%(61.8-64.4) and 64.7(63.2-66.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. One-year persistence was 65.9%(65.4-66.5), 63.4%(62.8-64.0), 61.4%(58.3-64.2), 72.3%(70.9-73.7) and 78.7%(77.1-80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing comorbidity was associated with reduced risk of non-adherence and non-persistence, across all OACs. Overall rates of “primary non-adherence”(stopping after first prescription), “non-adherent non-persistence” and “persistent adherence” were 3.5%, 26.5% and 40.2%, differing across OACs.Conclusions: Adherence and persistence to OACs are low at one year with heterogeneity across drugs and over time, at individual and system levels. Better understanding of contributory factors will inform interventions to improve adherence and persistence across OACs in individuals and populations.Key words: atrial fibrillation, anticoagulant, adherence, persistence, stroke

AB - Background: Despite simpler regimes than vitamin K antagonists(VKA) for stroke prevention in atrial fibrillation(AF), adherence(taking drugs as prescribed) and persistence(continuation of drugs) to direct oral anticoagulants(DOACs) are suboptimal, yet understudied in electronic health records(EHR). Objective: We investigated: (i)time trends at individual and system levels; (ii)risk factors for and associations between adherence and persistence.Methods: In UK primary care EHR(The Health Information Network; 2011-2016), we investigated adherence and persistence at 1-year for OACs in adults with incident AF. Baseline characteristics were analysed by OAC and adherence/persistence status. Risk factors for non-adherence and non-persistence were assessed using Cox and logistic regression. Patterns of adherence and persistence were analysed. Results: Among 36652 individuals with incident AF, cardiovascular comorbidities(median CHA2DS2VASc 3) and polypharmacy(median number of drugs 6) were common. Adherence was 55.2%(95 CI 54.6-55.7), 51.2%(50.6-51.8), 66.5%(63.7-69.2), 63.1%(61.8-64.4) and 64.7(63.2-66.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. One-year persistence was 65.9%(65.4-66.5), 63.4%(62.8-64.0), 61.4%(58.3-64.2), 72.3%(70.9-73.7) and 78.7%(77.1-80.1) for all OACs, VKA, dabigatran, rivaroxaban and apixaban. Risk of non-adherence and non-persistence increased over time at individual and system levels. Increasing comorbidity was associated with reduced risk of non-adherence and non-persistence, across all OACs. Overall rates of “primary non-adherence”(stopping after first prescription), “non-adherent non-persistence” and “persistent adherence” were 3.5%, 26.5% and 40.2%, differing across OACs.Conclusions: Adherence and persistence to OACs are low at one year with heterogeneity across drugs and over time, at individual and system levels. Better understanding of contributory factors will inform interventions to improve adherence and persistence across OACs in individuals and populations.Key words: atrial fibrillation, anticoagulant, adherence, persistence, stroke

M3 - Article

JO - Heart

JF - Heart

SN - 1355-6037

ER -